Association of the Neutrophil Percentage-to-Albumin Ratio with All-Cause Mortality in Patients with Hypercapnic Respiratory Failure: A Prospective Cohort Study

中性粒细胞百分比与白蛋白比值与高碳酸血症呼吸衰竭患者全因死亡率的相关性:一项前瞻性队列研究

阅读:1

Abstract

BACKGROUND: The neutrophil percentage-to-albumin ratio (NPAR) has emerged as a widely used inflammatory marker for predicting clinical outcomes across various diseases; however, its prognostic value in hypercapnic respiratory failure (HRF) remains uncertain. This study aimed to examine the association between NPAR and all-cause mortality in patients with HRF. METHODS: This prospective cohort study enrolled 561 HRF patients hospitalized at Yancheng First People's Hospital between October 2020 and September 2021. The primary outcome was 24-month all-cause mortality; secondary outcomes included mortality at 3, 6, and 12 months. The association between NPAR and all-cause mortality was assessed using restricted cubic spline (RCS) modeling, multivariate Cox proportional hazards models, Kaplan-Meier survival analysis, and subgroup analyses. Discriminatory performance was evaluated using the area under the receiver operating characteristic curve (AUC). RESULTS: RCS modeling demonstrated a significant linear association between NPAR and all-cause mortality in HRF patients (P for overall association < 0.001). Both the Cox models and Kaplan-Meier analyses indicated that elevated NPAR levels were significantly associated with increased 3-, 6-, 12-, and 24-month all-cause mortality (all P < 0.05). Subgroup analysis further supported an independent association between NPAR and mortality. The AUC for NPAR in predicting 12-month all-cause mortality was 0.66 (95% confidence interval [CI], 0.61-0.71), which was significantly higher than that of neutrophil percentage or albumin alone (AUC =0.62; 95% CI, 0.57-0.67; P < 0.05). CONCLUSION: Elevated NPAR is independently associated with increased all-cause mortality in patients with HRF. As a composite marker reflecting both systemic inflammation and nutritional status, NPAR may serve as a robust prognostic indicator to enhance risk stratification and guide clinical decision-making in HRF management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。